ArticleJCO oncology advances

Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials.

Shreyas Kalantri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.